Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates

• Autores principales: Yani Berckmans (Autor), Yannick Hoffert (Autor), Ann Vankerckhoven (Autor), Erwin Dreesen (Autor), An Coosemans (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2023-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.
• Notes: 10.3390/pharmaceutics15071792; 1999-4923
• Keywords: ovarian cancer; drug repurposing; myeloid-derived suppressor cells; treatment strategies; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 15, Iss 7, p 1792 (2023)

The lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in high relapse rates. Additionally, clinical trials testing immunotherapy against OC have failed to reach significant results to date. The OC tumor microenvironment and specifically myeloid-derived suppressor cells (MDSC) are known to generate immunosuppression and inhibit the anti-tumor immune response following immunotherapy treatment. Our review aims to characterize potential candidate treatments to target MDSC in OC through drug-repurposing. A literature search identified repurposable compounds with evidence of their suppressing the effect of MDSC. A total of seventeen compounds were withheld, of which four were considered the most promising. Lurbinectedin, metformin, celecoxib, and 5-azacytidine have reported preclinical effects on MDSC and clinical evidence in OC. They have all been approved for a different indication, characterizing them as the most promising candidates for repurposing to treat patients with OC.